Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells

Investigational New Drugs

Volumn 29, Issue 4, 2011, Pages 544-553

  Wilmes, Anja ^a   Rawson, Pisana ^a   Peng, Lifeng ^a   McLauchlan, Danyl ^a   Northcote, Peter T ^a   Jordan, T William ^a   Miller, John H ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Cancer; Microtubule; Peloruside A; Proteome

Indexed keywords

MYC PROTEIN; NATURAL PRODUCT; PELORUSIDE A; PROTEOME; UNCLASSIFIED DRUG;

ANEUPLOIDY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MICROTUBULE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN FUNCTION;

BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; CELL CYCLE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HL-60 CELLS; HUMANS; LACTONES; MICROTUBULES; NEOPLASM PROTEINS; PROTEOME; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TUBULIN;

EID: 79959726944     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9387-5     Document Type: Article

References (45)

1. West LM, Northcote PT, Battershill CN (2000) Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 65:445-449 (Pubitemid 30061125)
2. Hood KA, Bäckström BT, West LM, Northcote PT, Berridge MV, Miller JH (2001) The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C. Anticancer Drug Des 16:155-166 (Pubitemid 34269750)
3. Miller JH, Rouwé B, Gaitanos TN, Hood KA, Crume KP, Bäckström BT, La Flamme AC, Berridge MV, Northcote PT (2004) Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T cells. Apoptosis 9:785-796 (Pubitemid 40941207)
4. Hood KA, West LM, Rouwé B, Northcote PT, Berridge MV, Wakefield SJ, Miller JH (2002) Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 62:3356-3360 (Pubitemid 34651377)
5. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667 (Pubitemid 9114288)
6. Spratlin J, Sawyer MB (2007) Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 61:222-229 (Pubitemid 46329429)
7. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15 (Pubitemid 23239390)
8. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP (1993) Taxol: mechanism of action and resistance. J Natl Cancer Inst Monogr 55:15-61
9. Gaitanos TN, Buey RM, Díaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH (2004) Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multi-drug-resistant cell lines. Cancer Res 64:5063-5067 (Pubitemid 39006519)
10. Huzil JT, Chik JK, Slysz GW, Freedman H, Tuszynski J, Taylor RE, Sackett DL, Schriemer DC (2008) A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol 378:1016-1030
11. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Prognan F, Hawkins E, Currie I, Davison M (2001) Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 1:377-396 (Pubitemid 33585112)
12. Lee KH, Yim EK, Kim CJ, Namkoong SE, Um SJ, Park JS (2005) Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol 98:45-53
13. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP (2003) Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 63:6928-6934 (Pubitemid 37322978)
14. Dowling P, Meleady P, Dowd A, Henry M, Glynn S, Clynes M (2007) Proteomic analysis of isolated membrane fractions from superinvasive cells. Biochim Biophys Acta 1774:93-101 (Pubitemid 46049136)
15. Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O (2007) Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30:1545-1551
16. Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH (2007) Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharmaceutics 4:269-280 (Pubitemid 46640603)
17. Karp NA, Spencer M, Lindsay H, O'Dell K, Lilley KS (2005) Impact of replicate types on proteomic expression analysis. J Proteome Res 4:1867-1871 (Pubitemid 41464817)
18. Young C, Truman P, Boucher M, Keyzers RA, Northcote P, Jordan TW (2009) The algal metabolite yessotoxin affects heterogeneous nuclear ribonucleoproteins in HepG2 cells. Proteomics 9:2529-2542
19. Peng L, Rawson P, McLauchlan D, Lehnert K, Snell R, Jordan TW (2008) Proteomic analysis of microsomes from lactating bovine mammary gland. J Proteome Res 7:1427-1432
20. Senthilnathan P, Padmanvathi R, Maqesh V, Sakthisekaran D (2006) Stabilization of membrane bound enzyme profiles and lipid peroxidation by Withania somnifera along with paclitaxel on benzo(a)pyrene induced experimental lung cancer. Cancer Sci 97:658-664
21. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB (2003) Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 42:5349-5357 (Pubitemid 36560431)
22. Burkhart CA, Kavallaris M, Horwitz SB (2001) The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471:1-9
23. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer 120:2078-2085 (Pubitemid 46555844)
24. Ohishi Y, Oda Y, Basaki Y, Kobayashi H, Wake N, Kuwano M, Tsuneyoshi M (2007) Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 105:586-592 (Pubitemid 46734190)
25. Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao TP, Khuri FR, Giannakakou P (2005) The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 65:3883-3893 (Pubitemid 40616370)
26. Westermann S, Weber K (2003) Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 4:938-947 (Pubitemid 37493642)
27. Rubin CI, Atweh GF (2004) The role of stathmin in the regulation of the cell cycle. J Cell Biochem 93:242-250 (Pubitemid 44264202)
28. Kozielski F, Skoufias DA, Indorato RL, Saoudi Y, Jungblut PR, Hustoft HK, Strozynski M, Thiede B (2008) Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5. Proteomics 8:289-300 (Pubitemid 351212328)
29. Winkelmann I, Nässl AM, Daniel H, Wenzel U (2008) Proteome response in HT-29 human colorectal cancer cells to two apoptosis-inducing compounds with different mode of action. Int J Cancer 22:2223-2232 (Pubitemid 351542324)
30. Curmi PA, Noguès C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Liderau R, Bieche I (2000) Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82:142-150 (Pubitemid 30008973)
31. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, Hsu HC (2006) Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209:549-558 (Pubitemid 44194570)
32. Thome-Kromer B, Bonk I, Klatt M, Nebrich G, Taufmann M, Bryant S, Wacker U, Köpke A (2003) Towards the identification of liver toxicity markers: a proteome study in human cell culture and rats. Proteomics 3:1835-1862 (Pubitemid 37305879)
33. Thiede B, Rudel T (2003) Proteome analysis of apoptotic cells. Mass Spectrom Rev 23:333-349
34. Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, Murray GI (2006) The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 1765:85-100
35. Holcik M, Gordon BW, Korneluk RG (2003) The internal ribosome entry site-mediated translation of antiapoptotic protein XIAP is modulated by the heterogeneous nuclear ribonucleoproteins C1 and C2. Mol Cell Biol 23:280-288 (Pubitemid 36008520)
36. Patry C, Bouchard L, Labrecque P, Gendron D, Lemieux B, Toutant J, Lapointe E, Wellinger R, Chabot B (2003) Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res 63:7679-7688 (Pubitemid 37466696)
37. Revil T, Pelletier J, Toutant J, Cloutier A, Chabot B (2009) Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform. J Biol Chem 284:21458-21467
38. Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M (2003) Proteome analysis of vinca alkaloid and resistance to acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J Biol Chem 278:45082-45093 (Pubitemid 37432640)
39. Crume KP, Miller JH, La Flamme AC (2007) Peloruside A, an anti-mitotic agent, specifically decreases TNF-α production by LPS-stimulated murine macrophages. Exp Biol Med 232:607-613 (Pubitemid 46683385)
40. Peiretti F, Bernot D, Lopez L, Bonardo B, Deprez-Beauclair P, Juhan-Vague I, Nalbone G (2003) Modulation of PAI-1 and proMMP-9 syntheses by soluble TNF and its receptors during differentiation of the human monocytic HL-60 cell line. J Cell Physiol 196:346-353 (Pubitemid 36775882)
41. Stone JR, Collins T (2002) Rapid phosphorylation of heterogeneous nuclear ribonucleoprotein C1/C2 in response to physiologic levels of hydrogen peroxide in human endothelial cells. J Biol Chem 277:15621-15628 (Pubitemid 34967833)
42. Villamarín S, Ferrer-Miralles N, Mansilla S, Priebe W, Portugal J (2002) Induction of G2/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochem Pharmacol 63:1251-1258 (Pubitemid 34311994)
43. Gatti G, Maresca G, Natoli M, Florenzano F, Nicolin A, Felsani A, D'Agnano I (2009) Myc prevents apoptosis and enhances endoreduplication induced by paclitaxel. PLoS ONE 4:e5442
44. Menssen A, Epanchintsev A, Lodygin D, Rezaei N, Jung P, Verdoodt B, Diebold J, Hermeking H (2007) C-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle 6:339-352
45. Ikui AE, Yang CP, Matsumoto T, Horwitz SB (2005) Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy. Cell Cycle 4:1385-1388 (Pubitemid 41437128)